The Chase Family Movement Disorders Center offers opportunities for active participation in innovative research in the field of Parkinson’s disease, Dystonia, Huntington’s disease, Essential tremor and other movement disorders through clinical trials.
We continue to seek new ways to manage symptoms, slow the progression and observe trends in neurodegenerative disorders through clinical trials, in collaboration with other movement disorders specialists throughout North America and Europe and research consortia. We have several ongoing clinical research studies as noted below, and eligible patients have the option to participate in these clinical trials.
We also are involved in mentoring students, providers and physicians-in-training who will serve the community in the future as neurologists, researchers or primary care clinicians.
Our Vernon location is currently participating in the following clinical trials. For more information on how to become an integral part of research, please contact our Clinical Research Nurse and Study Coordinator, Rachael Geoffrion, RN at 860.870.6385 x65503 or via email.
Protocol No: ND0612-317 (NeuroDerm BouNDless)
A phase 3 multicenter, randomized, active-controlled, double-blind, double-dummy, parallel-group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson’s disease experiencing motor fluctuations.
Protocol No: 718-CNP-202 (Sage Therapeutics - currently enrolling)
A Phase 2, randomized, placebo-controlled, double-blind study to evaluate the effects of SAGE-718 in Parkinson's disease cognitive impairment.